Texas Permanent School Fund Corp Acquires New Position in Hims & Hers Health, Inc. $HIMS

Texas Permanent School Fund Corp bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund bought 51,532 shares of the company’s stock, valued at approximately $2,569,000.

Other large investors have also modified their holdings of the company. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter valued at approximately $26,000. Quaker Wealth Management LLC acquired a new stake in Hims & Hers Health in the second quarter valued at $29,000. Bessemer Group Inc. boosted its position in shares of Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares in the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health during the 1st quarter worth $30,000. Finally, Skandinaviska Enskilda Banken AB publ grew its stake in shares of Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock worth $37,000 after purchasing an additional 600 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages recently commented on HIMS. UBS Group set a $32.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, November 4th. Leerink Partnrs raised shares of Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a report on Thursday, December 4th. Canaccord Genuity Group reiterated a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a research report on Friday, September 12th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a report on Monday, December 15th. Finally, Barclays started coverage on Hims & Hers Health in a research note on Monday, December 8th. They issued an “overweight” rating and a $48.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $45.50.

Hims & Hers Health Stock Up 2.1%

HIMS stock opened at $35.49 on Friday. The company has a debt-to-equity ratio of 1.67, a current ratio of 1.88 and a quick ratio of 1.64. The company’s 50 day simple moving average is $41.85 and its 200-day simple moving average is $48.49. Hims & Hers Health, Inc. has a 12 month low of $23.97 and a 12 month high of $72.98. The firm has a market capitalization of $8.08 billion, a PE ratio of 65.72, a P/E/G ratio of 7.03 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $598.98 million for the quarter, compared to analyst estimates of $578.99 million. Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company’s revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 earnings per share. Equities analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has approved a stock buyback program on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to repurchase up to 3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company’s board believes its shares are undervalued.

Insiders Place Their Bets

In related news, Director Garcia Andrea G. Perez sold 2,500 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $39.17, for a total transaction of $97,925.00. Following the sale, the director owned 80,166 shares of the company’s stock, valued at $3,140,102.22. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Deborah M. Autor sold 7,054 shares of Hims & Hers Health stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the sale, the insider owned 6,175 shares of the company’s stock, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 233,429 shares of company stock valued at $11,769,372. Insiders own 13.71% of the company’s stock.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers announced a roughly US$200 million investment to expand its New Albany, Ohio operations — a move reporters say could quietly redefine its core strategy by expanding fulfillment/operational capacity and creating ~400 jobs. Investors often view large, strategic capacity investments as potential drivers of revenue growth and margin improvement over time. Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)?
• Positive Sentiment: The company has an active share-repurchase program — the board authorized up to $250M (about 3% of shares) — which can support the stock by reducing float and signaling management confidence in valuation. Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Neutral Sentiment: Analyst / media cautions: a Zacks piece flagged HIMS among high-growth medtech/telehealth names that could slow in 2026 — a reminder that momentum names carry execution and multiple-compression risk. 3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
• Neutral Sentiment: Large institutional ownership remains significant (e.g., Farallon, Invesco increased stakes), which can stabilize share demand but also concentrate price action; this is background context for liquidity and investor flows. HIMS company page (MarketBeat)
• Negative Sentiment: Several insiders sold shares on Dec. 17 (including Deborah Autor, Irene Becklund, Patrick Carroll and COO Michael Chi) — transactions together total roughly $1.4M+ and include large percentage reductions for some insiders. Concentrated insider selling, particularly from senior executives, can spook momentum traders and suggests some tax/liquidity-driven exits or portfolio trimming. Hims & Hers Health (NYSE:HIMS) Insider Sells $258,952.34 in Stock

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.